Download PDF
Geburtshilfe Frauenheilkd 2016; 76(02): 134-144
DOI: 10.1055/s-0041-111788
Guideline
GebFra Science
Georg Thieme Verlag KG Stuttgart · New York

Gestational and Non-gestational Trophoblastic Disease. Guideline of the DGGG, OEGGG and SGGG (S2k Level, AWMF Registry No. 032/049, December 2015)

Gestationsbedingte und nicht gestationsbedingte Trophoblasterkrankungen. Leitlinie der DGGG, OEGGG und SGGG (S2k-Level, AWMF-Registernummer 032/049, Dezember 2015)
C. Tempfer
1   Universitätsfrauenklinik der Ruhr-Universität Bochum, Bochum
,
L.-C. Horn
2   Institut für Pathologie, Universitätsklinikum Leipzig, Leipzig
,
S. Ackermann
3   Frauenklinik, Klinikum Darmstadt, Darmstadt
,
M. W. Beckmann
4   Frauenklinik, Universitätsklinikum Erlangen, Erlangen
,
R. Dittrich
4   Frauenklinik, Universitätsklinikum Erlangen, Erlangen
,
J. Einenkel
5   Universitätsfrauenklinik, Universitätsklinikum Leipzig, Leipzig
,
A. Günthert
6   Frauenklinik, Luzerner Kantonsspital, Lucerne, Switzerland
,
H. Haase
7   Frauenselbsthilfe nach Krebs, e. V.
,
J. Kratzsch
8   Institut für Laboratoriumsmedizin, Klinische Chemie und Molekulare Diagnostik, Universitätsklinikum Leipzig, Leipzig
,
M. C. Kreissl
9   Klinik für Nuklearmedizin, Klinikum Augsburg, Augsburg
,
S. Polterauer
10   Universitätsfrauenklinik, Medizinische Universität Wien, Vienna, Austria
,
A. D. Ebert
11   Praxis für Gynäkologie und Geburtshilfe, Berlin
,
K. T. M. Schneider
12   Abteilung für Geburtshilfe und Perinatalmedizin, Klinium rechts der Isar, Technische Universität München, Munich
,
H. G. Strauss
13   Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Halle (Saale), Halle (Saale)
,
F. Thiel
14   Frauenklinik, Alb Fils Kliniken, Göppingen
› Author Affiliations
Further Information

Publication History

Publication Date:
29 February 2016 (online)

Also available at
   Permissions and Reprints

Abstract

Purpose: The aim was to establish an official interdisciplinary guideline, published and coordinated by the German Society of Gynecology and Obstetrics (DGGG). The guideline was developed for use in German-speaking countries. In addition to the Germany Society of Gynecology and Obstetrics, the guideline has also been approved by the Swiss Society of Gynecology and Obstetrics (SGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). The aim was to standardize diagnostic procedures and the management of gestational and non-gestational trophoblastic disease in accordance with the principles of evidence-based medicine, drawing on the current literature and the experience of the colleagues involved in compiling the guideline. Methods: This s2k guideline represents the consensus of a representative panel of experts with a range of different professional backgrounds commissioned by the DGGG. Following a review of the international literature and international guidelines on trophoblastic tumors, a structural consensus was achieved in a formalized, multi-step procedure. This was done using uniform definitions, objective assessments, and standardized management protocols. Recommendations: The recommendations of the guideline cover the epidemiology, classification and staging of trophoblastic tumors; the measurement of human chorionic gonadotropin (hCG) levels in serum, and the diagnosis, management, and follow-up of villous trophoblastic tumors (e.g., partial mole, hydatidiform mole, invasive mole) and non-villous trophoblastic tumors (placental site nodule, exaggerated placental site, placental site tumor, epitheloid trophoblastic tumor, and choriocarcinoma).

Zusammenfassung

Ziel: Erstellung einer offiziellen, internationalen, interdisziplinären Leitlinie, publiziert und koordiniert von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). Die Leitlinie wurde für den deutschsprachigen Raum entwickelt und wird neben der DGGG auch von der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe (SGGG) und der Österreichischen Geselllschaft für Gynäkologie und Geburtshilfe (OEGGG) mitgetragen. Ziel der Leitlinie war es, die Diagnostik und Therapie von gestationsbedingten und nicht gestationsbedingten Trophoblasterkrankungen anhand der aktuellen Literatur sowie der Erfahrung der beteiligten Kolleginnen und Kollegen evidenzbasiert zu standardisieren. Methoden: Anhand der internationalen Literatur und unter Verwendung internationaler Leitlinien zum Thema Trophoblasttumore entwickelten die Mitglieder der beteiligten Fachgesellschaften im Auftrag der Leitlinienkommission der DGGG in einem strukturierten Prozess einen formalen Konsensus. Dies erfolgte unter Verwendung von einheitlichen Definitionen, objektivierten Bewertungsmöglichkeiten und standardisierten Therapieprotokollen. Empfehlungen: Die Empfehlungen der Leitlinie betreffen die Epidemiologie, Klassifikation und Stadieneinteilung von Trophoblasttumoren, die Bestimmung von humanem Choriongonadotropin (hCG) sowie die Diagnose, Therapie und Nachsorge von villösen Trophoblasttumoren (Partialmole, Blasenmole, invasive Mole) und nicht villösen Trophoblasttumoren (Plazentabett-Knoten, hyperplastische Implantationsstelle, Plazentabett-Tumor, epitheloider Trophoblasttumor und Chorionkarzinom).

Key words

trophoblastic tumor - mole - hydatidiform mole - human chorionic gonadotropin - treatment recommendations

Schlüsselwörter

Trophoblasttumor - Mole - Blasenmole - hCG - Therapieempfehlung

Supporting Information

 

  • References

  • 1 Mangili G, Lorusso D, Brown J et al. Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup. Int J Gynecol Cancer 2014; 24 (9 Suppl. 3) S109-S116
    CrossrefPubMedGoogle Scholar
  • 2 Seckl MJ, Sebire NJ, Fisher RA et al. ESMO Guidelines Working Group. Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl. 06) vi39-vi50
    PubMedGoogle Scholar
  • 3 Ngan HY, Bender H, Benedet JL et al. FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification. Int J Gynaecol Obstet 2003; 83 (Suppl. 01) 175-177
    CrossrefPubMedGoogle Scholar
  • 4 El-Helw LM, Coleman RE, Everard JE et al. Impact of the revised FIGO/WHO system on the management of patients with gestational trophoblastic neoplasia. Gynecol Oncol 2009; 113: 306-311
    CrossrefPubMedGoogle Scholar
  • 5 Savage P, Cooke R, OʼNions J et al. Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J Clin Oncol 2015; 33: 472-478
    CrossrefPubMedGoogle Scholar
  • 6 Tham BW, Everard JE, Tidy JA et al. Gestational trophoblastic disease in the Asian population of Northern England and North Wales. BJOG 2003; 110: 555-559
    CrossrefPubMedGoogle Scholar
  • 7 Braga A, Uberti EM, Fajardo Mdo C et al. Epidemiological report on the treatment of patients with gestational trophoblastic disease in 10 Brazilian referral centers: results after 12 years since International FIGO 2000 Consensus. J Reprod Med 2014; 59: 241-247
    PubMedGoogle Scholar
  • 8 Lybol C, Thomas CM, Bulten J et al. Increase in the incidence of gestational trophoblastic disease in The Netherlands. Gynecol Oncol 2011; 121: 334-338
    CrossrefPubMedGoogle Scholar
  • 9 Maestá I, Berkowitz RS, Goldstein DP et al. Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2015; 138: 50-54
    CrossrefPubMedGoogle Scholar
  • 10 Whittington J, Fantz CR, Gronowski AM et al. The analytical specificity of human chorionic gonadotropin assays determined using WHO International Reference Reagents. Clin Chim Acta 2010; 411: 81-85
    CrossrefPubMedGoogle Scholar
  • 11 Cole LA, Sutton JM, Higgins TN et al. Between-method variation in human chorionic gonadotropin test results. Clin Chem 2004; 50: 874-882
    CrossrefPubMedGoogle Scholar
  • 12 Cole LA, DuToit S, Higgins TN. Total hCG tests. Clin Chim Acta 2011; 412: 2216-2222
    CrossrefPubMedGoogle Scholar
  • 13 Harvey RA, Mitchell HD, Stenman UH et al. Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med 2010; 55: 285-295
    PubMedGoogle Scholar
  • 14 Stenman UH, Tiitinen A, Alfthan H et al. The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update 2006; 12: 769-784
    CrossrefPubMedGoogle Scholar
  • 15 Sutton JM. Charge variants in serum and urine hCG. Clin Chim Acta 2004; 341: 199-203
    CrossrefPubMedGoogle Scholar
  • 16 Cole LA, Laidler LL, Muller CY. USA hCG reference service, 10-year report. Clin Biochem 2010; 43: 1013-1022
    CrossrefPubMedGoogle Scholar
  • 17 Vassilakos P, Riotton G, Kajii T. Hydatidiform mole: two entities. A morphologic and cytogenetic study with some clinical consideration. Am J Obstet Gynecol 1977; 127: 167-170
    CrossrefPubMedGoogle Scholar
  • 18 Hoffner L, Surti U. The genetics of gestational trophoblastic disease: a rare complication of pregnancy. Cancer Genet 2012; 205: 63-77
    CrossrefPubMedGoogle Scholar
  • 19 Vogel M, Horn LC. [Gestational trophoblastic disease, Villous gestational trophoblastic disease]. Pathologe 2004; 25: 269-279
    PubMedGoogle Scholar
  • 20 Flam F, Lundström V, Pettersson F. Medical induction prior to surgical evacuation of hydatidiform mole: is there a greater risk of persistent trophoblastic disease?. Eur J Obstet Gynecol Reprod Biol 1991; 42: 57-60
    CrossrefPubMedGoogle Scholar
  • 21 Tidy JA, Gillespie AM, Bright N et al. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000; 78: 309-312
    CrossrefPubMedGoogle Scholar
  • 22 Berkowitz RS, Goldstein DP. Clinical practice. Molar pregnancy. N Engl J Med 2009; 360: 1639-1645
    CrossrefPubMedGoogle Scholar
  • 23 Sun SY, Melamed A, Goldstein DP et al. Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?. Gynecol Oncol 2015; 138: 46-49
    CrossrefPubMedGoogle Scholar
  • 24 Lybol C, Sweep FC, Harvey R et al. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia. Gynecol Oncol 2012; 125: 576-579
    CrossrefPubMedGoogle Scholar
  • 25 Alifrangis C, Agarwal R, Short D et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol 2013; 31: 280-286
    CrossrefPubMedGoogle Scholar
  • 26 Garrett LA, Garner EI, Feltmate CM et al. Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. J Reprod Med 2008; 53: 481-486
    PubMedGoogle Scholar
  • 27 Vargas R, Barroilhet LM, Esselen K et al. Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy, and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center. J Reprod Med 2014; 59: 188-194
    PubMedGoogle Scholar
  • 28 Baergen RN, Rutgers JL, Young RH et al. Placental site trophoblastic tumor: a study of 55 cases and review of the literature emphasizing factors of prognostic significance. Gynecol Oncol 2006; 100: 511-520
    CrossrefPubMedGoogle Scholar
  • 29 Shih IM, Kurman RJ. The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol 2001; 20: 31-47
    CrossrefPubMedGoogle Scholar
  • 30 Menczer J, Livoff A, Malinger G et al. Exaggerated placental site erroneously diagnosed as non-metastatic trophoblastic disease. A case report. Eur J Gynaecol Oncol 1999; 20: 115-116
    PubMedGoogle Scholar
  • 31 Nigam S, Dass R. Exaggerated placental site reaction mimicking choriocarcinoma. Acta Obstet Gynecol Scand 2003; 82: 587-588
    CrossrefPubMedGoogle Scholar
  • 32 Dotto J, Hui P. Lack of genetic association between exaggerated placental site reaction and placental site trophoblastic tumor. Int J Gynecol Pathol 2008; 27: 562-567
    CrossrefPubMedGoogle Scholar
  • 33 Papadopoulos AJ, Foskett M, Seckl MJ et al. Twenty-five yearsʼ clinical experience with placental site trophoblastic tumors. J Reprod Med 2002; 47: 460-464
    PubMedGoogle Scholar
  • 34 Feltmate CM, Genest DR, Wise L et al. Placental site trophoblastic tumor: a 17-year experience at the New England Trophoblastic Disease Center. Gynecol Oncol 2001; 82: 415-419
    CrossrefPubMedGoogle Scholar
  • 35 Chang YL, Chang TC, Hsueh S et al. Prognostic factors and treatment for placental site trophoblastic tumor-report of 3 cases and analysis of 88 cases. Gynecol Oncol 1999; 73: 216-222
    CrossrefPubMedGoogle Scholar
  • 36 Piura E, Piura B. Brain metastases from gestational trophoblastic neoplasia: review of pertinent literature. Eur J Gynaecol Oncol 2014; 35: 359-367
    PubMedGoogle Scholar
  • 37 Kohorn EI. Worldwide survey of the results of treating gestational trophoblastic disease. J Reprod Med 2014; 59: 145-153
    PubMedGoogle Scholar
  • 38 Schmid P, Nagai Y, Agarwal R et al. Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet 2009; 374: 48-55
    CrossrefPubMedGoogle Scholar
  • 39 Davis MR, Howitt BE, Quade BJ et al. Epithelioid trophoblastic tumor: a single institution case series at the New England Trophoblastic Disease Center. Gynecol Oncol 2015; 137: 456-461
    CrossrefPubMedGoogle Scholar
  • 40 Shih IM, Kurman RJ. Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol 1998; 22: 1393-1403
    CrossrefPubMedGoogle Scholar
  • 41 Shih IM, Seidman JD, Kurman RJ. Placental site nodule and characterization of distinctive types of intermediate trophoblast. Hum Pathol 1999; 30: 687-694
    CrossrefPubMedGoogle Scholar
  • 42 Zhang X, Lü W, Lü B. Epithelioid trophoblastic tumor: an outcome-based literature review of 78 reported cases. Int J Gynecol Cancer 2013; 23: 1334-1338
    CrossrefPubMedGoogle Scholar
  • 43 Horn LC, Bilek K, Pretzsch G et al. Choriocarcinoma in extrauterine tubal pregnancy. Geburtsh Frauenheilk 1994; 54: 375-377
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Horn LC, Vogel M. Gestational trophoblastic disease. Non-villous forms of gestational trophoblastic disease. Pathologe 2004; 25: 281-291
    PubMedGoogle Scholar
  • 45 Taylor F, Short D, Winter MC et al. A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom. Gynecol Oncol 2015; 136: 258-263
    CrossrefPubMedGoogle Scholar
  • 46 Yang J, Xiang Y, Wan X et al. The prognosis of gestational trophoblastic neoplasia patient with residual lung tumor after completing treatment. Gynecol Oncol 2006; 103: 479-482
    CrossrefPubMedGoogle Scholar
  • 47 Doll KM, Soper JT. The role of surgery in the management of gestational trophoblastic neoplasia. Obstet Gynecol Surv 2013; 68: 533-542
    CrossrefPubMedGoogle Scholar
  • 48 Soper JT. Role of surgery and radiation therapy in the management of gestational trophoblastic disease. Best Pract Res Clin Obstet Gynaecol 2003; 17: 943-957
    CrossrefPubMedGoogle Scholar
  • 49 Sebire NJ, Seckl MJ. Immunohistochemical staining for diagnosis and prognostic assessment of hydatidiform moles: current evidence and future directions. J Reprod Med 2010; 55: 236-246
    PubMedGoogle Scholar
  • 50 Tsai HW, Lin CP, Chou CY et al. Placental site nodule transformed into a malignant epithelioid trophoblastic tumour with pelvic lymph node and lung metastasis. Histopathology 2008; 53: 601-604
    PubMedGoogle Scholar
  • 51 Kaur B, Short D, Fisher RA et al. Atypical placental site nodule (APSN) and association with malignant gestational trophoblastic disease; a clinicopathologic study of 21 cases. Int J Gynecol Pathol 2015; 34: 152-158
    CrossrefPubMedGoogle Scholar
  • 52 Akbulut M, Tosun H, Soysal ME et al. Endometrioid carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature. Arch Gynecol Obstet 2008; 278: 79-84
    CrossrefPubMedGoogle Scholar
  • 53 Nguyen CP, Levi AW, Montz FJ et al. Coexistent choriocarcinoma and malignant mixed mesodermal tumor of the uterus. Gynecol Oncol 2000; 79: 499-503
    CrossrefPubMedGoogle Scholar
  • 54 Massenkeil G, Crombach G, Dominik S et al. Metastatic choriocarcinoma in a postmenopausal woman. Gynecol Oncol 1996; 61: 432-437
    CrossrefPubMedGoogle Scholar
  • 55 Carta G, Accurti V, Di Nicola M et al. Uterine endometrioid carcinoma with focal area of choriocarcinomatous differentiation: case report. Eur J Gynaecol Oncol 2014; 35: 731-733
    PubMedGoogle Scholar
  • 56 Horn LC, Hänel C, Bartholdt E et al. Serous carcinoma of the endometrium with choriocarcinomatous differentiation: a case report and review of the literature indicate the existence of 2 prognostically relevant tumor types. Int J Gynecol Pathol 2006; 25: 247-251
    CrossrefPubMedGoogle Scholar